Optimizing clinical trial design for multiple system atrophy: lessons from the rifampicin study.

Area of Science:

• Neurodegenerative Diseases
• Clinical Trial Design
• Pharmacology

Background:

• Multiple System Atrophy (MSA) is a fatal neurodegenerative disorder with no current treatments to slow progression.
• Clinical trials for MSA are challenged by the need for large patient cohorts, often necessitating international multi-center approaches.
• Uncertainty in patient numbers required for adequate statistical power has hindered disease-modifying treatment development.

Purpose of the Study:

• To identify and apply strategies to enhance statistical power and reduce the number of patients needed for Multiple System Atrophy (MSA) trials.
• To enable an oligocenter (fewer sites) approach for conducting clinical trials in MSA.
• To inform future trial designs by analyzing data from a recently conducted rifampicin trial in MSA.

Main Methods:

• Implemented specific inclusion/exclusion criteria to enroll patients with early, actively progressing MSA.
• Focused on minimizing patient dropouts and reducing variability in outcome scoring.
• Utilized pre-defined interim analyses to monitor trial progress.
• Employed a multi-center approach with rigorous site selection and training.

Main Results:

• The trial design allowed for a number needed to treat of only 50 patients per treatment arm.
• Recruitment goals were met within 12 months across ten selected sites.
• Achieved a dropout rate below 10% and successfully enrolled patients with actively progressing disease.

Conclusions:

• The strategies employed successfully improved trial power and feasibility for MSA studies.
• Data from this trial, though negative, provides valuable insights for powering future research.
• Recommendations for further improving trial design include rigorous site management, enhanced training, and the development of biomarkers for earlier diagnosis and progression tracking.